JOIN US LIVE MARCH 18! Whether you join us in the Bonie J. Addario Lung Cancer Foundation’s (ALCF) Living Room or attend remotely through Ustream on your computer, you will be informed about living with lung cancer.
Dr. DeCamp specializes in Thoracic Surgery, Minimally-invasive Surgery (Robotics & Advanced Laparoscopy) and Sterotactic Body Radiotherapy at the Robert H. Lurie Comprehensive Cancer Center.
His collaborative translational research focuses on using their human lung cancer biorepository to characterize regulatory Tcell populations (Tregs) and mast cells (MC) in human lung tumors and serum seeking to correlate the degree of inflammation and pro-inflammatory cytokine levels as potential biomarkers of cancer prognosis and/or as potential targets for therapeutic manipulation. They are also using their prospectively acquired clinical database to evaluate the effect common co-morbid diseases and their treatment (e.g. diabetes and hyperlipidemia) exert on lung cancer recurrence and survival following surgical treatment.
In his 2013 publication entitled, Molecular profiling in non-small call lung cance: a step toward personalized medicine,”Development of personalized approaches for the treatment of non-small cell lung carcinoma (NSCLC) mandates that pathologists make a precise histologic classification inclusive of routine molecular analysis of such tumors. Objective: To address the molecular mechanisms underlying NSCLC and how this knowledge reflects the multidisciplinary approach in the diagnosis and management of these patients. We will also summarize the current available and investigational personalized therapies for patients with resectable
early-stage, unresectable locally advanced, and metastatic NSCLC. Data Sources: Peer-reviewed published literature and personal experience. Conclusions: There are multiple mechanisms involved in the pathogenesis of lung cancer, which operate in parallel and involve pathways of activation and inhibition of various cellular events. Further research is essential to characterize the histologic and mutational profiles of lung carcinomas, which will ultimately translate into improved and more personalized therapeutic management of patients with lung cancer.